

# New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

## OSAP Recipient Meeting

August 20, 2019

**Peter Ryba, PharmD**

PMP Director  
peter.ryba@state.nm.us

PRESCRIPTION MONITORING PROGRAM

NEW MEXICO BOARD OF PHARMACY

### *Agenda*

---

- Prescription Drug Information and Statistics
- What is the PMP?
- PMP Related Regulatory Citations
- PMP Utilization Requirements
- Practitioner Evaluation of a Patient's PMP Report
- Other Laws
- Useful Links


PRESCRIPTION MONITORING PROGRAM  
NEW MEXICO BOARD OF PHARMACY

*Prescription Drug Information and Statistics*

**Rx**

**249M**

prescriptions for opioids were written by healthcare providers in 2013




enough prescriptions for every American adult to have a bottle of pills

Since 1999, there have been more than

**165,000**

deaths from overdose related to prescription opioids.



Source: [www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)


PRESCRIPTION MONITORING PROGRAM  
NEW MEXICO BOARD OF PHARMACY

*Prescription Drug Information and Statistics*

The National Epidemic

- The United States is in the midst of an epidemic of prescription opioid overdose deaths, which killed more than 63,600 people in 2016 alone.

Sales of prescription opioids in the U.S. nearly **QUADRUPLED** from 1999 to 2014,



but the amount of pain Americans reported remained **UNCHANGED**

Source: NCHS Data Brief, Number 294, December 2017

[www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)

PRESCRIPTION MONITORING PROGRAM  
NEW MEXICO BOARD OF PHARMACY


### Prescription Drug Information and Statistics

---

The State of New Mexico compared to the United States average

- In 2014, New Mexico had the **second** highest drug overdose death rate (27.3 deaths per 100,000 age-adjusted population).
- In 2015, New Mexico had the **eighth** highest drug overdose death rate (25.3 deaths per 100,000 age-adjusted population).
- In 2016, New Mexico had the **twelfth** highest drug overdose death rate (25.2 deaths per 100,000 age-adjusted population).
- In 2017, New Mexico had the **seventeenth** highest drug overdose death rate (24.8 deaths per 100,000 age-adjusted population).

Source: [www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)



PRESCRIPTION MONITORING PROGRAM  
NEW MEXICO BOARD OF PHARMACY

### Prescription Drug Information and Statistics

Although New Mexico has been progressing, NM is still statistically higher compared to the United States drug overdose death rate average (21.7 deaths per 100,000).

U.S. rate is 19.8 per 100,000 standard population.

- Statistically lower than U.S. rate
- Statistically the same as U.S. rate
- Statistically higher than U.S. rate

Source: NCHS Data Brief, Number 294, December 2017



PRESCRIPTION MONITORING PROGRAM  
NEW MEXICO BOARD OF PHARMACY



### Prescription Drug Information and Statistics



*Age-Adjusted Drug Overdose Death Rates, by Opioid Category: United States 1999-2016*



Year	Synthetic opioids other than methadone <sup>1</sup>	Natural and semisynthetic opioids <sup>1</sup>	Heroin <sup>1</sup>	Methadone <sup>2</sup>
1999	0.2	1.0	0.5	0.5
2000	0.3	1.0	0.5	0.5
2002	0.5	1.5	0.8	0.5
2004	0.8	1.8	1.2	0.5
2006	1.0	2.5	1.8	0.5
2008	1.2	3.0	1.5	0.5
2010	1.5	3.5	1.2	0.5
2012	2.0	3.5	1.0	0.5
2014	3.0	4.0	1.0	0.5
2016	6.2	4.5	1.0	0.5

Source: NCHS Data Brief, Number 294, December 2017


















PRESCRIPTION MONITORING PROGRAM  
NEW MEXICO BOARD OF PHARMACY

### What is the PMP?

The New Mexico Prescription Monitoring Program is a web-based electronic database that aids in the reporting of dispensed controlled substance prescription information.

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*What is the PMP?*

---

## Mission

To provide practitioners, pharmacists, and other authorized users the ability to review a patient's controlled substance prescription history and assist in the prevention of diversion, abuse, misuse, and drug overdose deaths associated with controlled substance prescriptions.

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Registration Process*

---

Registrants include:

- Healthcare Professionals
- Delegates
  - Up to four (4) delegates per practitioner/pharmacist
  - A delegate can have an unlimited number of practitioners/pharmacists
- Law Enforcement
- Regulatory Board Agents
- Medicaid Compliance Officers

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Related Regulatory Citations*

---

DENTISTRY (DENTISTS, DENTAL HYGIENISTS, ETC.)

[16.5.57 NMAC - MANAGEMENT OF PAIN WITH CONTROLLED SUBSTANCES](#)

MEDICINE AND SURGERY PRACTITIONERS

[16.10.14 - NMAC MANAGEMENT OF PAIN WITH CONTROLLED SUBSTANCES](#)

MIDWIVES

[16.11.2 NMAC - CERTIFIED NURSE MIDWIVES](#)

NURSING AND HEALTH CARE RELATED PROVIDERS

[16.12.9 NMAC - MANAGEMENT OF CHRONIC PAIN WITH CONTROLLED SUBSTANCES](#)

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Related Regulatory Citations*

---

OPTOMETRIC PRACTITIONERS

[16.16.15 NMAC - MANAGEMENT OF PAIN WITH CONTROLLED SUBSTANCES](#)

OSTEOPATHIC MEDICINE AND SURGERY PRACTITIONERS

[16.17.4 NMAC - PRESCRIBING AND DISTRIBUTION OF CONTROLLED SUBSTANCES](#)

PHARMACISTS

[16.19.4 NMAC - PHARMACIST](#)

[16.19.20 NMAC - CONTROLLED SUBSTANCES](#)

[16.19.29 NMAC - CONTROLLED SUBSTANCE PRESCRIPTION MONITORING PROGRAM](#)

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Related Regulatory Citations*

---

## PODIATRISTS

[16.21.9 NMAC - MANAGEMENT OF PAIN WITH CONTROLLED SUBSTANCES](#)

## PSYCHOLOGISTS

[16.22.30 NMAC - MANAGEMENT OF PAIN WITH CONTROLLED SUBSTANCES](#)

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Utilization Requirements*

---

*All Users*

- Only authorized account holder can access the NM PMP.
- Sharing login information is a violation of both federal and state regulations.
- Although delegates can pull PMP patient reports on behalf of a practitioner, the practitioner is ultimately responsible to review the PMP patient report.
- The practitioner shall document the review of the PMP patient report as required per their licensing board regulation.

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Utilization Requirements*

*Medical Board Licensees (e.g. physicians, physician assistants)*

- For the initial controlled substance II-V prescription and if the day supply is greater than four (4) days, or if there is a gap in prescribing any controlled substance for 30 days or more, obtain and review the NM PMP patient report for the previous 12 months and from adjacent states if available.
- For a renewal or continuous use of a controlled substance II-V, obtain and review a NM PMP patient report no less than once every three months.
- Document your review!

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Utilization Requirements*

*Medical Board Licensees (e.g. physicians, physician assistants)*

- Practitioners licensed to practice in an opioid treatment program shall review a PMP patient report upon initial enrollment into the opioid treatment program and every three (3) months thereafter while prescribing, ordering, administering, or dispensing opioid treatment medication in schedules II-V.
- Document your review!

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Utilization Requirements*

*Medical Board Licensees (e.g. physicians, physician assistants)*

Practitioners do not have to consult the PMP report before prescribing, ordering, or dispensing a controlled substance II-V:

- If the dispensed quantity is for a period of 4 days or less, or
- To a patient in a nursing facility, or
- To a patient in hospice care, or
- When prescribing, dispensing or administering:
  - Testosterone
  - Pregabalin
  - Lacosamide
  - Ezogabine
  - Stimulant therapy for pediatric patients less than age 14

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*PMP Utilization Requirements*

*Dispensers*

- All dispensers (e.g. pharmacies, dispensing practitioners) must report within one business day if more than 12 doses within a 72 hour period was dispensed.
- If a dispenser did not dispense any controlled substances, a "zero report" must be submitted within one business day.
- If a dispenser becomes aware of an data entry error, the correction must be submitted to the PMP within five (5) business days.

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*Practitioner Evaluation of a Patient's PMP Report*

---

- Multiple providers and/or pharmacies
- Prescriptions obtained from nonlocal providers and/or pharmacies
- High doses of opioids
- Opioids in combination with other sedating substances (e.g. benzodiazepines)
- Early refill requests
- Cash payments when insurance is available

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*Electronic Prescribing of Controlled Substances (EPCS)*

---

## EPCS

- In 2017, 90% of non-controlled substances were prescribed electronically; however, only 21% of controlled substances were prescribed electronically.
- All Medicare Part D controlled substance prescription must be electronically prescribed by January 1, 2021.
- Visit <https://getepcs.com/> to learn more.



## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*SB 221*

---

- 2019 Legislature passed Senate Bill 221, which adds new language into the Pain Relief Act.
- Governor Michelle Lujan Grisham signed this bill on March 28<sup>th</sup>, and this became **law effective June 14, 2019.**

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*SB 221*

---

This law will require health care providers who prescribe, distribute or dispense a prescription opioid **to a patient for the first time:**

- advise the patient on the risks of overdose and inform the availability of an opioid antagonist (i.e. naloxone);
- co-prescribe an opioid antagonist (i.e. naloxone), if the prescription for the opioid is at least a five-day supply; and,
- provide written information about the opioid antagonist, how to administer the opioid antagonist, and that 911 should be called immediately after administration.

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*SB 221*

This law will require health care providers who prescribe, distribute or dispense a prescription opioid **to a patient for the previously on opioids**:

- advise the patient on the risks of overdose and inform the availability of an opioid antagonist (i.e. naloxone) on the first occasion of each calendar year;
- co-prescribe an opioid antagonist (i.e. naloxone), if the prescription for the opioid is at least a five-day supply; and,
- provide written information about the opioid antagonist, how to administer the opioid antagonist, and that 911 should be called immediately after administration.

## PRESCRIPTION MONITORING PROGRAM

## NEW MEXICO BOARD OF PHARMACY

*Useful Links*

NM Board of Pharmacy      <http://www.rld.state.nm.us/boards/Pharmacy.aspx>  
 PMP Registration and FAQs      <http://www.nmpmp.org/>  
 PMP AWARxE      <https://newmexico.pmpaware.net/login>

## Support

Technical Customer Service (24/7/365)	1-844-366-4767
Local Non-Technical (M-F 8a-5p)	505-222-9847
NM BOP PMP Support	<a href="mailto:nm.pmp@state.nm.us">nm.pmp@state.nm.us</a>

PRESCRIPTION MONITORING PROGRAM  
NEW MEXICO BOARD OF PHARMACY

*Questions?*

---